Journal
COLLOIDS AND SURFACES B-BIOINTERFACES
Volume 148, Issue -, Pages 576-584Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.colsurfb.2016.09.029
Keywords
BCR/ABL fusion gene; Biosensor; Electrochemistry; Hybrid nanoparticles; Leukemia
Funding
- Brazilian National Council for Scientific and Technological Development (CNPq)
- Rede ELINOR de Nanobiotecnologia/CAPES
- MCT/FINEP
- PROPESQ/UFPE
- [FACEPE-PPSUS-APQ-0040-4.00/13]
Ask authors/readers for more resources
In the last ten years, conjugated polymers started to be used in the immobilization of nucleic acids via non-covalent interactions. In the present study, we describe the construction and use of an electrochemical DNA biosensor based on a nanostructured polyaniline-gold composite, specifically developed for the detection of the BCR/ABL chimeric oncogene. This chromosome translocation is used as a biomarker to confirm the clinical diagnosis of both chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL). The working principle of the biosensor rests on measuring the conductivity resulting from the non-covalent interactions between the hybrid nanocomposite and the DNA probe. The nanostructured platform exhibits a large surface area that enhances the conductivity. Positive cases, which result from the hybridization between DNA probe and targeted gene, induce changes in the amperometric current and in the charge transfer resistance (R-CT) responses. Atomic force microscopy (AFM) images showed changes in the genosensor surface after exposure to cDNA sample of patient with leukemia, evidencing the hybridization process. This new hybrid sensing-platform displayed high specificity and selectivity, and its detection limit is estimated to be as low as 69.4 aM. The biosensor showed excellent analytical performance for the detection of the BCR/ABL oncogene in clinical samples of patients with leukemia. Hence, this electrochemical sensor appears as a simple and attractive tool for the molecular diagnosis of the BCR/ABL oncogene even in early-stage cases of leukemia and for the monitoring of minimum levels of residual disease. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available